{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:00Z","timestamp":1777934700779,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite treatment modalities for multiple myeloma can cause adverse drug reactions (ADRs), data are scarce about the types, severity and preventability of chemotherapy-related ADRs in Kenya. This study aimed to assess the chemotherapy-related ADRs among multiple myeloma patients at Kenyatta National Hospital (KNH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A one-arm retrospective cohort study was carried out among all eligible adult patients with a documented diagnosis of multiple myeloma between 1\n                      <jats:sup>st<\/jats:sup>\n                      January 2017 to 31\n                      <jats:sup>st<\/jats:sup>\n                      December 2023. A data abstraction tool was used to assess sociodemographics, clinical characteristics and chemotherapy-related ADRs. The Schumock and Thornton scale and the modified Hartwig and Siegel severity scale were employed to evaluate the preventability and severity of ADRs, respectively. Data analysis was performed using the Statistical Package for Social Sciences (SPSS) version 29.0 software. The results were presented using mean, frequency and percentage. Binary logistic regression was employed to assess factors influencing ADRs. A p-value of less than 0.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of ADRs in this study was 81.5% with a total of 230 ADRs identified. The primary ADRs identified were peripheral neuropathy (21.7%), nausea and vomiting (14.8%), neutropenia (12.2%) and anemia (11.3%). The majority of the ADRs (51.7%) were moderate in severity, and 29.8% were of mild severity. Preventability assessments of the ADRs showed that most of them (68.2%) were definitely preventable and 13.2% were probably preventable. VRD (Bortezomib\/Lenalidomide\/Dexamethasone) and VCD (Bortezomib\/Cyclophosphamide\/Dexamethasone) treatment regimens were responsible for most of the ADRs. VRD (AOR = 11.1, 95% CI\u2009=\u20093.7\u201332.8, p\u2009&lt;\u20090.001) and VCD treatment regimens (AOR = 4.8, 95% CI\u2009=\u20091.1\u201320.0, p\u2009=\u20090.033) were the significant factors affecting the occurrence of ADRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, the incidence of chemotherapy-related ADRs in multiple myeloma patients at KNH was notably high (81.5%). Despite the moderate severity of the ADRs, their preventable nature highlights the potential for improved patient outcomes through careful regimen selection and monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241276438","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:32:56Z","timestamp":1725669176000},"page":"1051-1060","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of chemotherapy-related adverse drug reactions among multiple myeloma patients at Kenyatta national hospital"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9034-045X","authenticated-orcid":false,"given":"Epifania Amedeus","family":"Assenga","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0548","authenticated-orcid":false,"given":"Amsalu","family":"Degu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin A","family":"Omolo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya"},{"name":"Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020059"},{"key":"e_1_3_3_3_2","volume-title":"Key Statistics for Multiple Myeloma","author":"American Cancer Society","year":"2023","unstructured":"American Cancer Society. Key Statistics for Multiple Myeloma. American Cancer Society, 2023."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-021-00088-3"},{"key":"e_1_3_3_5_2","first-page":"236","article-title":"Towards a unified approach for multiple myeloma care in Kenya-proceedings of the inaugural multiple myeloma congress","volume":"2021","author":"Lotodo TC","unstructured":"Lotodo TC, Melly BJ, Manyega KM, et al. Towards a unified approach for multiple myeloma care in Kenya-proceedings of the inaugural multiple myeloma congress. Pan Afr Med J 2021; 40: 236.","journal-title":"Pan Afr Med J"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-5-481"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12870"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/life12010048"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221995532"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.1000"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1152-y"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1577822"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13756"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0624"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000532"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000343950"},{"key":"e_1_3_3_17_2","first-page":"538","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock GT","year":"1992","unstructured":"Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.","journal-title":"Hosp Pharm"},{"key":"e_1_3_3_18_2","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229\u20132232.","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.177015"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14417"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0157"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21306"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.875607"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0953"},{"key":"e_1_3_3_25_2","volume-title":"Multiple Myeloma","author":"Albagoush SA","year":"2023","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. Treasure Island, FL: StatPearls Publishing, 2023."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052759"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4314\/gmj.v53i1.8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.194"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020977763"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20165128"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-018-2782-0"},{"key":"e_1_3_3_34_2","first-page":"39","article-title":"Nurse\u2019s Knowledge and Practice of Chemotherapy Induced Nausea and Vomiting Management amongPatients with Respiratory Malignancy - A Descriptive Study","volume":"4","author":"Maemunah S","year":"2020","unstructured":"Maemunah S, Pompey CS. Nurse\u2019s Knowledge and Practice of Chemotherapy Induced Nausea and Vomiting Management amongPatients with Respiratory Malignancy - A Descriptive Study. UI Proc Heal Med 2020; 4: 39\u201343.","journal-title":"UI Proc Heal Med"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.15171\/jcs.2019.024"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320970354"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.53730\/ijhs.v6nS8.13431"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5198"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijstd.IJSTD_116_17"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023005"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.217569"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12946"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13238"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","unstructured":"Stork CM Schreffler SM. Cyclophosphamide. 2023. In: StatPearls [Internet]. Treasure Island FL: StatPearls Publishing; 2024.","DOI":"10.1016\/B978-0-12-824315-2.00542-X"},{"key":"e_1_3_3_47_2","article-title":"Recurrent drug-induced hypersensitivity syndrome following bortezomib for multiple myeloma","volume":"13","author":"Ambur AB","year":"2021","unstructured":"Ambur AB, Nathoo R. Recurrent drug-induced hypersensitivity syndrome following bortezomib for multiple myeloma. Cureus 2021; 13: e20830.","journal-title":"Cureus"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1118-x"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.15226\/2476-2431\/2\/1\/00114"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616672572"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000833"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219891209"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220914710"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101144"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0040-1"},{"key":"e_1_3_3_56_2","article-title":"Development of an Adverse Drug Reaction Risk Assessment Score among Hospitalized Patients with Chronic Kidney Disease","volume":"9","author":"Sharif-Askari FS","year":"2014","unstructured":"Sharif-Askari FS, Sulaiman SAS, Sharif-Askari NS, et al. Development of an Adverse Drug Reaction Risk Assessment Score among Hospitalized Patients with Chronic Kidney Disease. PLoS One 2014; 9: e95991.","journal-title":"PLoS One"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/308316"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.06.008"},{"key":"e_1_3_3_59_2","article-title":"An account of acute adverse drug reactions occurring in a day-care chemotherapy unit of a tertiary care cancer hospital-a prospective observational study","author":"Sekhar GP","year":"2022","unstructured":"Sekhar GP, Mallavarapu KM, Rajappa S, et al. An account of acute adverse drug reactions occurring in a day-care chemotherapy unit of a tertiary care cancer hospital-a prospective observational study. Indian J Med Paediatr Oncol 2022.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"e_1_3_3_60_2","first-page":"1306","article-title":"Parenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur","volume":"2019","author":"Ang ZY","unstructured":"Ang ZY, Cheah KY, Abdullah NB, et al. Parenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur. How Much and why? 2019; 26: 1306\u20131317.","journal-title":"How Much and why?"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241276438","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:13Z","timestamp":1777689013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241276438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241276438"],"URL":"https:\/\/doi.org\/10.1177\/10781552241276438","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}